Latest News for: wet amd

Edit

Cascade Prodrug and Uneedle Advance Collaboration to Enable Suprachoroidal Delivery of CPD100 for Wet AMD

Nasdaq Globe Newswire 08 Jul 2026
Cascade Prodrug and Uneedle advance CPD100 for wet AMD using Bella-Vue suprachoroidal delivery, with preclinical work underway ... .
Edit

Wet AMD Pipeline Gains Momentum: 60+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

GetNews 07 Jul 2026
Inactive Products Wet Age-Related Macular Degeneration (Wet-AMD) Key Companies Wet Age-Related Macular Degeneration (Wet-AMD) Key Products Wet Age-Related Macular Degeneration (Wet-AMD)- Unmet Needs ...
Edit

Wet Age-related Macular Degeneration (Wet AMD) Pipeline 2025

GetNews 03 Jul 2026
Download the Wet AMD pipeline report to learn more about the emerging Wet AMD therapies ... Wet AMD current marketed and Wet AMD emerging therapies ... Wet AMD market drivers and Wet AMD market barriers.
Edit

Wet Age-related Macular Degeneration (Wet AMD) Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial ...

GetNews 30 Jun 2026
Download the Wet AMD pipeline report to learn more about the emerging Wet AMD therapies ... Wet AMD current marketed and Wet AMD emerging therapies ... Wet AMD market drivers and Wet AMD market barriers.
Edit

4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD

Nasdaq Globe Newswire 29 Jun 2026
... global program, evaluating 4D-150 in patients with wet age-related macular degeneration (wet AMD).
Edit

Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second Half of 2026

PR Newswire 25 Jun 2026
Proceeds from the Series B financing will support global Phase 3 development of OLN324, a next-generation VEGF/Ang2 bispecific antibody, in DME and wet AMD, as well as the advancement of another drug candidate into clinical development this year.
Edit

Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD (Form 8-K) (Outlook Therapeutics Inc)

Public Technologies 16 Jun 2026
Treatment for Wet AMD ... age-related macular degeneration (nAMD), or wet AMD ... ONS-5010/LYTENAVA™ is an ophthalmic formulation of bevacizumab produced in the United States for the treatment of wet AMD.
Edit

Wet AMD Market Set for Robust Growth Through 2036, Driven by Advancements in Anti-VEGF Therapies | DelveInsight

PR Newswire 27 May 2026
Total Prevalent Cases of AMD, Stage-specific Prevalent Cases of AMD, Total Prevalent Cases of Wet-AMD, Total Diagnosed Prevalent Cases of Wet-AMD, Age-specific Diagnosed Prevalent Cases of Wet-AMD, and Total Treated Cases of Wet-AMD.
Edit

EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, ...

Nasdaq Globe Newswire 14 May 2026
– LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after – ... .
Edit

EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data (Form 8-K) (EyePoint Inc)

Public Technologies 14 May 2026
Such statements include, but are not limited to, statements regarding our expectations regarding our clinical development and regulatory plans; our belief that DURAVYU™ is well-positioned to be the ...
Edit

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

Nasdaq Globe Newswire 29 Apr 2026
SOL-X long-term extension trial in wet AMD enrolled the first subject in April 2026 who had successfully completed the two-year SOL-1 trial ... .
  • 1

Article Search

tools
×
×
×
×